Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAS181 in Immunocompromised Patients with Parainfluenza
NCT01924793Phase 2Completed
- Sponsor
- Ansun Biopharma
- Start
- Aug 2013
- Primary completion
- May 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of DAS181 in parainfluenza virus infection, sponsored by Ansun Biopharma. Started Aug 2013; status: completed.
02
Drugs
DAS181
03
Conditions
parainfluenza virus infection
Beyond the preview
Go deeper on NCT01924793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01924793.